Rigel Pharmaceuticals
RIGL
#7356
Rank
S$0.44 B
Marketcap
$25.07
Share price
4.96%
Change (1 day)
62.97%
Change (1 year)

P/E ratio for Rigel Pharmaceuticals (RIGL)

P/E ratio as of April 2025 (TTM): -86.6

According to Rigel Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -86.6364. At the end of 2022 the company had a P/E ratio of -44.1.

P/E ratio history for Rigel Pharmaceuticals from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-44.1-83.35%
2021-26521.14%
2020-219308.88%
2019-53.54.67%
2018-51.1-19.64%
2017-63.697.77%
2016-32.2-37.37%
2015-51.4133.02%
2014-22.0-21.9%
2013-28.2-42.26%
2012-48.9-13.9%
2011-56.8-155.03%
2010103-397.2%
2009-34.758.79%
2008-21.9-77.79%
2007-98.425.19%
2006-78.695.58%
2005-40.2-48.65%
2004-78.3104.24%
2003-38.3184.51%
2002-13.5-35.11%
2001-20.8

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-27.5-68.25%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.5659-99.35%๐Ÿ‡บ๐Ÿ‡ธ USA
35.0-140.44%๐Ÿ‡ฌ๐Ÿ‡ง UK
19.8-122.83%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.